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OBJECTIVE — Both short and long sleep duration have frequently been found to be associ-
ated with an increased risk for diabetes. The aim of the present exploratory analysis was to
examinetheassociationbetweensleepdurationandtype2diabetesafterlifestyleinterventionin
overweight individuals with impaired glucose tolerance in a 7-year prospective follow-up.
RESEARCH DESIGN AND METHODS — A total of 522 individuals (aged 40–64
years) were randomly allocated either to an intensive diet-exercise counseling group or to a
control group. Diabetes incidence during follow-up was calculated according to sleep duration
atbaseline.Sleepdurationwasobtainedfora24-hperiod.Physicalactivity,dietaryintakes,body
weight, and immune mediators (C-reactive protein and interleukin-6) were measured.
RESULTS — Interaction between sleep duration and treatment group was statistically signif-
icant (P  0.003). In the control group, the adjusted hazard ratios (HRs) (95% CI) for diabetes
were 2.29 (1.38–3.80) and 2.74 (1.67–4.50) in the sleep duration groups 9–9.5 h and 10 h,
respectively, compared with for that of the 7–8.5 h group. In contrast, sleep duration did not
inﬂuence the incidence of diabetes in the intervention group; for sleep duration groups 9–9.5 h
and 10 h, the adjusted HRs (95% CI) were 1.10 (0.60–2.01) and 0.73 (0.34–1.56), respec-
tively, compared with that in the reference group (7–8.5 h sleep). Lifestyle intervention resulted
in similar improvement in body weight, insulin sensitivity, and immune mediator levels regard-
less of sleep duration.
CONCLUSIONS — Long sleep duration is associated with increased type 2 diabetes risk.
Lifestyle intervention with the aim of weight reduction, healthy diet, and increased physical
activity may ameliorate some of this excess risk.
Diabetes Care 32:1965–1971, 2009
I
t has become increasingly evident that
abnormal sleep patterns, such as short
and long sleep durations, are associ-
ated with increased morbidity and mor-
tality (1). The relationship between
increased risk for type 2 diabetes and ei-
ther short or long sleep has frequently
been demonstrated in both men and
women (2–4). The underlying mecha-
nisms are still largely unknown. In an ex-
perimental study, sleep deprivation has
been shown to have harmful effects on
metabolic and endocrine functions (5).
However, there are no plausible physio-
logical or psychosocial explanations for
theassociationbetweenlongsleepanddi-
abetes. In fact, some studies have ob-
served a stronger association between
habitual long sleep and diabetes than that
for short sleep (2,3). There is no evidence
orconsensuswhethertherelationshipbe-
tween long sleep and diabetes is causal or
simply reﬂects confounding by other un-
derlyingfactorsthataffectsleepinghabits.
However, there is growing evidence that
many of the hypothesized factors for long
sleep are strongly associated with obesity
and metabolic syndrome (6,7). The ob-
jective of the present exploratory analysis
wastoexaminetheeffectoflifestyleinter-
vention on the association between sleep
duration and type 2 diabetes in individu-
als with impaired glucose tolerance (IGT)
in the Finnish Diabetes Prevention Study
(DPS) (8,9).
RESEARCH DESIGN AND
METHODS— This report is a sub-
study of a larger lifestyle intervention
trial,inwhich522overweightindividuals
with IGT were randomly allocated to an
intensivediet-exercisegroup(n265)or
a control group (n  257). At baseline,
participants’ mean  SD BMI was 31.1 
4.5kg/m
2andagewas557years.There
were no signiﬁcant differences in clinical
features between the two groups. More
details on the study design can be found
in previously published reports (8,9).
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Theparticipantsintheintensiveinterven-
tion group were given detailed, individu-
alized counseling to achieve the lifestyle
goals: 1) weight reduction 5%, 2)
30% of the daily energy intake from fat,
3) 10% of the daily energy intake from
saturated fat, 4) ﬁber intake 15 g/1,000
kcal, and 5) moderately intense physical
activity 30 min daily. The participants in
the control group were given general oral
andwrittenadviceaboutdietandexercise
at baseline, but no speciﬁc individualized
advice was offered to them. The interven-
tion period lasted for a median of 4 years,
after which a postintervention follow-up
lasting for a median of 3 years was carried
out (9).
Sleep duration and anthropometric
assessments
Before each annual examination, partici-
pants completed an activity diary cover-
ing all activities (divided into eight
categories)duringthepast24h.Duration
of activities was recorded to the nearest
half hour. Time spent sleeping or resting
in bed was considered as an individual’s
daily sleep duration. Measurements of
height, weight, waist circumference, and
bloodpressurehavebeendescribedinde-
tail previously (8,9).
Assessment of dietary intake and
physical activity
Study participants completed 3-day
food records at the baseline and before
each annual visit. The physical activity
was calculated based on the Leisure-
Time Physical Activity questionnaire
(10). The details of both dietary intake
and physical activity assessments and
calculationscanbefoundinearlierpub-
lications (8,9).
Blood sampling and laboratory
measurements
Bloodwastakenfromtheantecubitalvein
with the participant in a sitting position
and allowed to clot at room temperature
for 30–60 min. After centrifugation at
8,000–11,000g, sera were stored at
70°C for analyses although for logistic
reasons,storageat20°Cwasallowedfor
a maximum of 3 months. The annually
measured biochemical parameters in-
cluded an 75-g oral glucose tolerance test
after 12 h of fasting in the morning with
fasting and 2-h plasma glucose measure-
ments. Diabetes was deﬁned according to
the World Health Organization 1985 cri-
teria (11). The diagnosis of diabetes had
to be conﬁrmed by a second oral glucose
tolerance test. Serum concentrations
of high-sensitivity C-reactive protein
(CRP) were assessed by an immunon-
ephelometricassay(DadeBehring,Mar-
burg, Germany) (12). Interleukin-6
(IL-6) concentrations in serum were de-
termined by enzyme-linked immu-
nosorbentassayusingrecombinantIL-6
and an antibody pair (Sanquin, Amster-
dam, Netherlands) (12).
Statistical methods
Sleep duration was grouped as 6.5 h,
7–8.5 h, 9–9.5 h, and 10 h. Diabetes
incidence per 100 person-years was cal-
culated in each sleep duration group. The
Cox proportional hazards model was
used to compare the development of dia-
betes in different sleep duration catego-
ries. The average sleep duration for an
adult in Finland is 7.5 h (13), and there-
fore the group 7–8.5 h was used as refer-
ence category. In a multivariate Cox
model, the relationship between diabetes
and sleep duration was further explored
by taking into account possible con-
founding factors including 1) age, sex,
study center, and BMI at baseline and 2)
age, sex, BMI, study center, smoking, al-
cohol intake, hypertension medication,
leisure-time physical activity at baseline,
and 1-year change in body weight. The
interaction between treatment group and
sleep duration at baseline was tested to
assess whether the intervention modiﬁed
the relationship between sleep duration
and diabetes incidence. In addition, the
effect of treatment and sleep on diabetes
was analyzed using the annual sleep du-
ration assessments with the Cox propor-
tional hazards regression model, treating
the repeated measurements on sleep du-
ration as a time-varying covariate. Analy-
ses were done with the statistics package
Stata (release 9.2, 2005; StataCorp, Col-
lege Station, TX).
RESULTS— Age was directly associ-
ated with sleep duration in both treat-
ment groups (Table 1). The patients with
longer sleep duration were more likely to
have a nap during the daytime and med-
ication for hypertension; otherwise the
treatment groups had no statistically sig-
niﬁcant differences in baseline character-
isticsbetweenthedifferentsleepduration
groups. However, there was a tendency
toward more frequent smoking, alcohol
usage, and physical activity in long sleep-
ers (10 h) compared with other sleep
duration groups.
Sleepdurationatbaselinewasnotsig-
niﬁcantly associated with body weight
(Table 1) and did not predict weight
change over 3 years (Table 2). Neither
were there signiﬁcant differences in CRP
or IL-6 levels at the follow-up visit be-
tween different sleep duration groups.
The intervention resulted in parallel im-
provements in body weight, waist cir-
cumference, immune mediator levels,
and insulin sensitivity over the follow-up
in all of the sleep groups.
Small changes in the mean sleeping
time during the follow-up were observed
(Table 2). The long sleepers (10 h) in
the control group slept even more,
whereas the sleeping time was reduced in
long sleepers in the intervention group.
However, the changes were minor, and
there was no signiﬁcant shifting from one
sleep duration group to another in either
the control or intervention group. Over
the 1-year follow-up, the proportion of
long-sleepingparticipants(10h)taking
a nap during the daytime decreased from
74% to a mere 30% with similar changes
in both treatment groups. During the fol-
low-up, the physical activity of long
sleepers was signiﬁcantly reduced in the
control group only, but the interaction
term indicates that the difference was
nonsigniﬁcant between both treatment
groups.Thechangesindietbasedonfood
diaries in the intervention group were
similar in different sleep duration groups.
A total of 182 participants developed
diabetes during the follow-up (Table 3).
The interaction between treatment group
and sleep duration at baseline was statis-
ticallysigniﬁcant(adjustedP0.003).In
the control group only, there was a statis-
tically signiﬁcant difference in diabetes
incidence rates between the sleep dura-
tion groups (log-rank test P  0.001)
(Fig. 1). For the sleep duration groups
9–9.5 and 10 h, the adjusted hazard
ratios (HRs) were 2.29 (95% CI 1.38–
3.80)and2.74(1.67–4.50),respectively,
compared with that in the reference
group (7–8.5 h sleep) (Table 3). In con-
trast,nosigniﬁcantdifferencesindiabetes
incidence among the sleep duration
groups in the intervention group were
seen. In the intervention group, the ad-
justed HRs were 1.10 (0.60–2.01) and
0.73 (0.34–1.56) for the sleep duration
groups 9–9.5 and 10 h, respectively,
compared with that in the reference
group (7–8.5 h sleep) (Table 3). A ten-
dency toward an increased diabetes risk
in individuals with short sleep (6.5 h)
was also observed (Table 3). In a Cox
Sleep duration and incidence of type 2 diabetes
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duration assessments included as time-
varying covariates, the interaction term
between treatment group and sleep dura-
tion was still statistically signiﬁcant (ad-
justed P  0.028).
Daytime sleepiness, as measured by
sleeping and resting in bed during the
daytime (0900–1900), predicted diabe-
tes incidence in the control group but not
in the intervention group (Pinteraction 
0.001). However, when total sleep dura-
tion was simultaneously accounted for,
daytime sleepiness was no longer associ-
ated with diabetes incidence in the con-
trol group (P  0.526).
CONCLUSIONS — In this post hoc
analysis of the DPS, we detected a signif-
icant association between long sleep du-
ration and incident type 2 diabetes in
overweight individuals with IGT in a
7-year follow-up. However, the associa-
tion was not observed in participants
receiving individualized lifestyle inter-
vention. The facts that 1) study partici-
pants with different sleep duration at
baseline did not differ in anthropometric,
metabolic, and immunological parame-
ters and that 2) changes in these parame-
ters were similar in both intervention and
control groups suggest that the associa-
tion between sleep duration and diabetes
risk was independent of these factors.
Short sleep duration as a possible
cause of diabetes incidence is plausible
givenresultsfromexperimentalstudiesin
healthy volunteers that have shown sleep
restriction to result in glucose intolerance
(5), which is a risk factor for the develop-
ment of insulin resistance. In the present
study, there was a tendency toward in-
creased diabetes risk in individuals with
short sleep, but it did not reach statistical
signiﬁcance compared with the reference
group. This could be because there was a
small number of participants with short
sleep and thus inadequate statistical
power to detect a difference or because
the short sleep category was deﬁned
somewhat broadly (6.5 h/night) and
was not particularly short compared with
the typically recommended sleep dura-
tion of 7–9/night.
Thusfar,thereisnocompellingphys-
iological evidence explaining the associa-
tion between long sleeping time and
increased morbidity and mortality. The
linkhasbeenobservedinepidemiological
studies, based on questionnaires without
objective sleep measurements. Therefore,
whether long sleep represents an increase
in actual sleeping time or just increased
time in bed cannot be deﬁnitely deter-
mined. The main underlying causes
proposed to potentially explain the
relationship have been obstructive sleep
apnea (OSA), depression, fatigue, low so-
cioeconomic status, heart diseases, and
inactivity(13–15).Oftheseproposedfac-
tors, sleep-disordered breathing including
OSA has been found to be independently
associated with insulin resistance (16). In
overweight patients with OSA, lifestyle
intervention with weight reduction has
been found to be an effective treatment
(17). An earlier analysis of the DPS re-
vealed that weight reduction also led to a
signiﬁcant improvement in insulin resis-
tance in patients with IGT (18). Alto-
gether, characteristics of the long sleepers
have been found to differ from those of
short or normal sleepers, and these ﬁnd-
ings tend to support many of the pro-
posed hypotheses (13,14). The long
sleepers in our study were observed to be
older and to take naps more frequently
and were more likely to be receiving an-
tihypertensive drug therapy than other
participants. Antihypertensive drugs,
particularly -blockers, have been re-
ported to have central nervous system ef-
Table 1—Characteristics of the DPS study participants by sleep duration at baseline
Sleep duration
P 6.5 h 7.0–8.5 h 9.0–9.5 h 10.0 h
n (%) 47 (9.1) 222 (43.1) 115 (22.3) 131 (25.4)
Age (years) 52.5  7.4 54.1  7.0 56.0  7.2 57.2  6.7 0.001
Sex (% male) 34.0 33.8 29.6 34.4 0.850
Smoking (%) 6.4 6.8 3.5 10.7 0.179
Sleep duration (h/24 h) 5.7  1.0 7.9  0.5 9.3  0.3 11.0  1.4 0.001
Nap during daytime (% participants) 10.6 25.7 47.8 74.8 0.001
BMI (kg/m
2) 31.9  4.9 31.2  4.6 31.8  4.9 30.5  3.9 0.081
Waist circumference (cm) 102.8  10.7 101.3  11.0 102.4  12.0 99.6  10.2 0.172
Systolic blood pressure (mmHg) 136.1  16.9 136.1  18.6 141.4  17.4 139.0  16.0 0.051
Diastolic blood pressure (mmHg) 86.2  10.7 85.3  10.0 86.0  9.4 86.0  9.0 0.874
Blood pressure medication (%) 17.0 25.7 30.7 38.9 0.014
Fasting plasma glucose (mmol/l) 6.1  0.9 6.1  0.7 6.1  0.7 6.2  0.8 0.890
2-h plasma glucose (mmol/l) 8.9  1.4 8.7  1.4 9.1  1.6 8.9  1.5 0.417
HOMA-IR 3.7  2.1 4.0  2.3 4.6  2.7 4.0  1.9 0.065
CRP (mg/l)* 2.6  2.7 1.9  2.9 2.5  2.7 2.3  2.6 0.091
IL-6 (pg/ml)* 1.7  2.2 1.8  2.5 2.0  2.5 1.6  2.2 0.411
Total LTPA (h/week) 6.8  5.1 6.8  5.4 7.1  6.0 8.2  7.1 0.164
Alcohol (g/day) 5.0  10.4 7.4  16.0 5.1  11.3 8.2  17.8 0.313
Total fat (energy %) 37.8  6.1 36.5  6.5 36.3  7.2 36.4  6.5 0.616
Saturated fat (energy %) 17.8  3.6 16.5  4.1 16.6  4.4 16.2  4.3 0.190
Carbohydrates (energy %) 42.9  6.3 43.3  7.1 44.1  7.5 43.1  7.2 0.643
Fiber (g/1,000 kcal) 12.3  4.8 11.7  3.9 11.7  3.7 11.5  4.1 0.690
Data are means  SD unless stated otherwise. *Geometric means. HOMA-IR, homeostasis model assessment of insulin resistance. LTPA, leisure-time physical
activity. *Geometric means.
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sleep disorders in some individuals (19).
In the present study, participants
with long sleep were more likely to take
naps during the daytime; a possible man-
ifestation of daytime sleepiness known to
be related with OSA. Over the follow-up
period, less long-sleeping participants
were observed to take a nap during the
daytime; however, the change was equal
between the treatment groups. In the in-
tervention group, participants with long-
sleep at baseline tended to sleep less over
follow-up and participants with short
sleep at baseline tended to sleep longer,
whereastheoppositeoccurredinthecon-
trol group. However, the overall changes
in sleep durations over the follow-up
were relatively small. The interaction
term between sleep duration and treat-
ment was still statistically signiﬁcant, in-
dicatingthattheeffectofinterventionwas
different among the different sleep dura-
tion categories.
Manyofthefactorsdocumentedtobe
associated with long sleep duration are
also associated with obesity and the met-
abolic syndrome (6,7). The association
between long sleep duration and diabetes
has been hypothesized to be due to the
effects of proinﬂammatory cytokines,
whichhavealsobeenfoundtobeelevated
in sleep-disordered breathing, depres-
sion, and excessive sleepiness, the sug-
gested confounding factors causing long
sleep (7,20,21). Furthermore, obesity it-
self is regarded as a chronic inﬂammatory
condition. The elevated levels of proin-
ﬂammatory cytokines have been consid-
ered to contribute to the increased sleep
duration (21). A previous report from the
Finnish DPS demonstrated that systemic
concentrations of immune mediators
were associated with the progression of
IGTtotype2diabetes,andtheprevention
of type 2 diabetes by lifestyle changes was
related to the decline in proinﬂammatory
factors. This decline, on the other hand,
was associated with increases in ﬁber in-
take and moderate to vigorous leisure
timephysicalactivity(12,22).Wedidnot
observe differences in CRP or IL-6 con-
centrations between the long sleep dura-
tion and the reference group at the
Table 2—Changes over 1-year follow-up among the DPS participants by sleep duration at baseline
Baseline sleep duration
P* Pinteraction† 6.5 h 7.0–8.5 h 9.0–9.5 h 10.0 h
Control group
n 27 116 47 62
Weight (kg) 0.13 1.15 1.61 0.41 0.218 —
Waist circumference (cm) 0.03 1.21 2.81‡ 1.11 0.092 —
Fasting plasma glucose (mmol/l) 0.18 0.01 0.05 0.07 0.458 —
2-h plasma glucose (mmol/l) 0.28 0.48 0.27 0.01 0.568 —
HOMA-IR 0.38 0.23 0.25 0.47 0.881 —
CRP (mg/l) 0.95 0.50 0.94 0.42 0.846 —
IL-6 (pg/ml) 0.10 0.18 0.12 0.39 0.935 —
Sleep duration (h/24 h) 1.2‡ 0.2 0.4 0.7‡ 0.032 —
Nap during daytime (% participants) 10.2 27.0 39.2 32.0 0.101 —
Total LTPA (h/week) 0.0 0.6 1.1 1.7‡ 0.038 —
Alcohol (g/day) 1.7 1.9 3.5 1.3‡ 0.034 —
Total fat (energy %) 2.8 2.0 2.2 2.1 0.946 —
Saturated fat (energy %) 2.1 1.3 1.1 1.1 0.717 —
Carbohydrates (energy %) 0.5 1.6 3.3 1.5 0.300 —
Fiber (g/1,000 kcal) 0.7 0.6 0.5 1.1 0.783 —
Intervention group
n 20 106 68 69
Weight (kg) 5.20 4.62 4.44 4.11 0.824 0.451
Waist circumference (cm) 3.59 4.15 4.06 5.37 0.349 0.176
Fasting plasma glucose (mmol/l) 0.15 0.19 0.28 0.27 0.613 0.687
2-h plasma glucose (mmol/l) 1.02 0.83 0.76 0.85 0.946 0.709
HOMA-IR 0.79 0.73 0.95 0.40 0.467 0.451
CRP (mg/l) 1.47 0.78 1.41 1.79 0.256 0.609
IL-6 (pg/ml) 0.46 0.56 0.11 0.39 0.883 0.871
Sleep duration (h/24 h) 0.9‡ 0.2 0.1 0.6 0.024 0.088
Nap during daytime (% participants) 44.7‡ 17.7 26.0 30.8 0.084 0.034
Total LTPA (h/week) 0.3 0.3 0.1 0.3 0.881 0.363
Alcohol (g/day) 1.2 3.3 5.2 3.3 0.277 0.488
Total fat (energy %) 5.5 3.2 2.9 3.8 0.410 0.803
Saturated fat (energy %) 3.7 2.6 2.5 2.8 0.554 0.960
Carbohydrates (energy %) 4.6 3.1 3.6 3.1 0.819 0.473
Fiber (g/1,000 kcal) 3.0 2.4 2.6 2.4 0.946 0.827
Dataaremeanchangesadjustedforbaselinelevelsoftherespectivevariable,exceptthedaytimenap,whichisreportedasprevalenceat1-yearfollow-up.HOMA-IR,
homeostasismodelassessmentofinsulinresistance;LTPA,leisure-timephysicalactivity.*Pvaluefortestofequalchangebetweenthesleepdurationgroups.†Pvalue
for test of interaction between sleep duration and treatment group. ‡P  0.05 compared with the 7.0–8.5 h group.
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both short and long sleepers compared
withthatinthereferencegroup;however,
the difference was not statistically signiﬁ-
cant. Neither were there any signiﬁcant
changes in CRP or IL-6 during the fol-
low-up in the long sleep duration group
compared with the reference group. In
theDPS,alloftheindividualsbelongedto
a high-risk group with overweight and
IGT and therefore do not represent a nor-
mal population cohort. Physical activity
Table 3—Incidence rates for type 2 diabetes by sleep duration at baseline
Baseline sleep duration
P* 6.5 h 7.0–8.5 h 9.0–9.5 h 10.0 h
Control group
Person-years of follow-up 154 747 260 319
No. of diabetes events 11 36 24 36
Incidence per 100 person-years 7.1 (4.0–12.9) 4.8 (3.5–6.7) 9.2 (6.2–13.8) 11.3 (8.1–15.6) 0.001
HR, unadjusted 1.51 (0.73–3.10) 1.0 1.99 (1.20–3.31) 2.43 (1.54–3.84)
HR, adjusted† 1.51 (0.73–3.12) 1.0 2.05 (1.25–3.38) 2.88 (1.82–4.57)
HR, adjusted‡ 1.68 (0.79–3.59) 1.0 2.29 (1.38–3.80) 2.74 (1.67–4.50)
Intervention group
Person-years of follow-up 126 678 467 460
No. of diabetes events 8 32 21 14
Incidence per 100 person-years 6.3 (3.2–12.7) 4.7 (3.3–6.7) 4.5 (2.9–6.9) 3.0 (1.8–5.1) 0.377
HR, unadjusted 1.34 (0.58–3.10) 1.0 0.93 (0.54–1.60) 0.65 (0.35–1.21)
HR, adjusted† 1.06 (0.46–2.46) 1.0 0.99 (0.57–1.71) 0.76 (0.40–1.44)
HR, adjusted‡ 1.44 (0.59–3.53) 1.0 1.10 (0.60–2.01) 0.73 (0.34–1.56)
Data in parentheses are 95% CI. *P value: log-rank test for equal incidence over sleep duration categories. †Adjusted for age, sex, BMI, and study center. ‡Adjusted
for age, sex, BMI, study center, smoking, alcohol intake, hypertension medication, leisure-time physical activity at baseline, and 1-year change in body weight.
Figure 1—The cumulative incidence of type 2 diabetes in follow-up time by sleep duration groups. A: Control group. B: Intervention group.
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thebaselineamongthedifferentsleepdu-
ration strata, and the changes during the
follow-up did not either differ among the
strata groups.
The assessment of sleep duration in
our study was based on a self-reported
activity questionnaire and not conﬁrmed
byobjectivemeasurements.Nevertheless,
questionnaireshavebeenfoundtobeuse-
ful in assessing sleep duration (23). The
activity diary used in the present study
covers all activities divided into eight cat-
egories,withoneofthosecategoriesbeing
sleeping or resting in bed (10). Thus, un-
fortunately, it is not possible to separate
them. However, in the present study the
data collected on sleep duration was ob-
tainedfora24-hperiod,includingnaps,a
possible manifestation of daytime sleepi-
ness. We have shown previously that life-
style intervention was effective in
lowering diabetes risk. The present anal-
yses reveal that the effect of intervention
was mainly limited to those with longer
baseline sleep duration. Because we ob-
servednointeractionbetweensleepdura-
tionandgroupassignmentondietaryand
physical activity behavior intervention,
this risk reduction apparently did not re-
sult from better adherence to interven-
tion. In clinical work more attention
should be paid to these conditions; along
with visual detection of obesity, physi-
cians may more effectively identify pa-
tients at high risk for diabetes with
questions about the sleep quality and
quantity.
Our results are in line with some pre-
vious reports suggesting that habitually
long sleep may be a surrogate marker of a
condition that is associated with an in-
creased risk for type 2 diabetes (14). It is
likely that a number of factors exist to ex-
plain the statistical association between
long sleep duration and diabetes.
Whether all the factors correlate to each
other is unclear, but most of them are
commonly related to fatigue, inactivity,
weightgain,andobesity.Insummary,the
present results suggest that some of the
type 2 diabetes risk among overweight
persons with IGT who also have long
sleep duration may be ameliorated by
weightreductionandanincreaseinphys-
ical activity and healthier diet.
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